In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $13.00. The company’s shares closed last Friday at $4.40.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 26.6% and a 51.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $12.57 average price target, implying a 167.4% upside from current levels. In a report issued on March 15, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.
CymaBay Therapeutics’ market cap is currently $316.2M and has a P/E ratio of -5.00. The company has a Price to Book ratio of 2.10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.